TE
TELA.O
—
NASDAQ
Diversified Medical Equipment & Supplies
TELA Bio Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
33,1M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-43,2 %
ROE
-615,1 %
Net margin
-48,4 %
Debt / equity
8,82
Beta
—
52w range
—
Volume
491
Day range
$0,89–$0,97
Prev close
$0,90
Open
$0,89
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
TEL Bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of fibrotic and inflammatory diseases.
Business. TELA Bio Inc (TELA.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, focusing on medical devices and related supplies. TELA Bio is listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic breakdowns are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target2,25
Analyst recommendations
5 analysts · consensus BuyBuy4
Hold1
Sell0
12-month price target
2,25
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
-615,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to TELA.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
TELA Bio Inc (TELA.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, focusing on medical devices and related supplies. TELA Bio is listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic breakdowns are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
AI synthesis
GENERATEDTEL Bio Inc operates with a high debt-to-equity ratio of 8.82, indicating a capital structure heavily reliant on debt financing. The company holds $50.85 million in cash and equivalents, but this is offset by $55.65 million in long-term debt, resulting in a net cash position of -$4.8 million. The current ratio of 4.2 suggests strong short-term liquidity, but the negative net cash position raises concerns about long-term solvency.
Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $38.83 million and an operating loss of $34.64 million, with a return on equity of -6.15% and a return on assets of -0.48%. These figures indicate that TELA is not generating returns that meet the cost of capital, a critical concern for investors.
TEL Bio Inc derives its revenue from a single therapeutic focus on fibrotic and inflammatory diseases, with no disclosed geographic diversification in the financial data. This concentration in a narrow therapeutic area and lack of geographic segmentation increases exposure to clinical trial risks and regulatory delays.
The company's growth trajectory is constrained by its current financial position. Revenue for the latest period was $80.28 million, but with a negative operating cash flow of $28.22 million and a free cash flow of -$38.27 million, TELA is not generating cash to fund operations or growth. Analysts have assigned a mean price target of $2.25, suggesting a potential upside of 127% from the current market price of $0.99.
Risk factors include the company's high leverage and negative net cash position, which could necessitate additional financing and potentially lead to dilution. The risk assessment flags net cash as negative after subtracting total debt, and while dilution is currently rated as low, the high debt-to-equity ratio and negative cash flow suggest potential for future dilution.
Recent events include the publication of financial results and analyst price targets, but no material corporate actions or regulatory developments were disclosed in the latest filings. The company remains in a pre-commercialization phase, with no revenue from product sales reported.
Key takeaways
- TELA Bio Inc is a high-risk, high-debt biopharmaceutical company with no positive returns on equity or assets.
- The company's reliance on debt financing and negative cash flow raise concerns about long-term solvency.
- Analysts have assigned a mean price target of $2.25, indicating potential for significant upside but also highlighting the speculative nature of the investment.
- The company's narrow therapeutic focus and lack of geographic diversification increase exposure to clinical and regulatory risks.
- TELA's capital structure and liquidity position suggest a need for additional financing, which could lead to future dilution.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,74
Market cap
$44.3M
Enterprise valueⓘ
$49.1M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
7.0x
P / Tangible bookⓘ
7.0x
Tangible book
$6.3M
Net cashⓘ
-$4.8M
Current ratioⓘ
4.2
Debt / equityⓘ
8.8
ROAⓘ
-47.7%
ROEⓘ
-6.2%
Cash conversionⓘ
73.0%
CapEx / revenueⓘ
-0.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Hernia Repair Devices—
low · business_description · 2026-07-03
Plastic & Reconstructive Surgery Devices—
low · business_description · 2026-07-03
Surgical Mesh & Fixation Devices—
low · business_description · 2026-07-03
Business relationships
Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries3
EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%
EX21:daa9777b5404EX21:daa9777b5404Subsidiarie97%
EX21:f95ee3e62a1eEX21:f95ee3e62a1eSubsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs TELA · multiples and returns
AB
ABT—
Abbott Laboratories
$107,13
187,2B USDP/E
26,3x
— vs self
Div yield
2,4 %
— vs self
ROE
12,5 %
+627,6 vs self
MD
MDT—
Medtronic PLC
$86,19
110,3B USDP/E
21,4x
— vs self
Div yield
3,4 %
— vs self
ROE
9,7 %
+624,8 vs self
MD
MDLN—
MEDLINE INC.
$40,47
53,2B USDP/E
202,6x
— vs self
Div yield
—
— vs self
ROE
—
— vs self
SY
SYK—
Stryker Corp
$341,20
131,8B USDP/E
38,0x
— vs self
Div yield
—
— vs self
ROE
13,5 %
+628,6 vs self
BD
BDX—
Becton Dickinson And Co
$170,21
48,4B USDP/E
25,6x
— vs self
Div yield
2,8 %
— vs self
ROE
7,0 %
+622,0 vs self
HS
HSIC—
Henry Schein Inc
$88,21
10,1B USDP/E
80,5x
— vs self
Div yield
—
— vs self
ROE
3,0 %
+618,1 vs self
BA
BAX—
Baxter International Inc
$28,10
14,5B USDP/E
—
— vs self
Div yield
2,3 %
— vs self
ROE
-15,4 %
+599,7 vs self
SO
SOLV—
SOLVENTUM CORPORATION
$76,83
13,3B USDP/E
8,6x
— vs self
Div yield
—
— vs self
ROE
30,8 %
+645,9 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,67
Predicted surprise
+0,00
Beat probability
45 %
Analysts
5
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,67 |
| Revenue | —no estimate | —no estimate | 86,8M USD |
| Operating income | —no estimate | —no estimate | -31,4M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution5 analysts
Strong buy1
Buy3
Hold1
Sell0
Strong sell0
12-month price target$2,25 · Median $2,00
Low $1,00High $3,25
Operating income · consensus-31,4M USD
EPS surprise
−23,5 %
reported vs consensus · miss
Revenue surprise
−7,6 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$1,00
Mean$2,25
Median$2,00
High$3,25
Spot$0,74
+204.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-43,2 %Below median
Net Margin-48,4 %Below median
ROE-615,1 %Bottom quartile
Capex / Rev-0,6 %Above median
D/E8,82Bottom quartile
Cash Conv0,73Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 822 310 sh17 grants11 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 335 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 550 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 335 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 335 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 550 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 335 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 335 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 550 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 335 @ $0,94grant · 2026-06-09
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 550 @ $0,94grant · 2026-06-09
- President · Stock Option (Right to Buy) → Common StockAcquired 127 000 @ $0,72grant · 2026-02-20
- COO and CFO · Stock Option (Right to Buy) → Common StockAcquired 85 000 @ $0,72grant · 2026-02-20
- Chief Technology Officer · Stock Option (Right to Buy) → Common StockAcquired 85 000 @ $0,72grant · 2026-02-20
- Chief Business Officer · Stock Option (Right to Buy) → Common StockAcquired 55 000 @ $0,72grant · 2026-02-20
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 261 000 @ $0,72grant · 2026-02-20
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 550 @ $1,23grant · 2025-10-31
- Director · Stock Option (Right to Buy) → Common StockAcquired 17 550 @ $1,48grant · 2025-10-09
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- TELA Bio Inc Market data — financials · 2026-05-29
- TELA Bio Inc Market data — analyst estimates · 2026-05-29
- TELA Bio Inc Market data — ESG · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
Net buying1 buys · 0 sellsnet $4,0M13 insiders · last 365d
- Director · Common StockOther 11 675 · 2026-06-09
- Director · Common StockOther 11 925 · 2026-06-09
- Director · Common StockOther 11 675 · 2026-06-09
- Director · Common StockOther 11 675 · 2026-06-09
- Director · Common StockOther 11 925 · 2026-06-09
- Director · Common StockOther 11 675 · 2026-06-09
- Director · Common StockOther 11 925 · 2026-06-09
- Director · Common StockOther 11 675 · 2026-06-09
- Director · Common StockOther 11 925 · 2026-06-09
- Director · Common StockOther 11 675 · 2026-06-09
- Director, Chief Executive Officer · Common StockOther 3 900 @ $0,79$3K · 2026-02-24
- Chief Business Officer · Common StockOther 1 352 @ $0,77$1K · 2026-02-23
- Chief Technology Officer · Common StockOther 4 061 @ $0,77$3K · 2026-02-23
- Chief Accounting Officer · Common StockOther 423 @ $0,77$324 · 2026-02-23
- COO and CFO · Common StockOther 5 234 @ $0,77$4K · 2026-02-23
- Director, Chief Executive Officer · Common StockOther 11 631 @ $0,77$9K · 2026-02-23
- Director, Chief Executive Officer · Common StockOther 12 494 @ $0,72$9K · 2026-02-21
- Chief Business Officer · Common StockOther 4 189 @ $0,72$3K · 2026-02-21
- Chief Technology Officer · Common StockOther 3 385 @ $0,72$2K · 2026-02-21
- COO and CFO · Common StockOther 4 780 @ $0,72$3K · 2026-02-21
- Chief Accounting Officer · Common StockOther 1 590 @ $0,72$1K · 2026-02-21
- COO and CFO · Common StockOther 57 000 · 2026-02-20
- Chief Business Officer · Common StockOther 37 000 · 2026-02-20
- President · Common StockOther 86 000 · 2026-02-20
- Director, Chief Executive Officer · Common StockOther 176 000 · 2026-02-20
Short positioning
361.8Kshares short-22.4% vs prior
4.96days to cover
48.2%short of daily vol
4.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
TELA.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Gross margin (FY 2025-12-31): 67.7%Derived (calculated)
- Net margin (FY 2025-12-31): -48.3%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 35.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 16.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 37.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 37.6%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -3.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -54.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 11.90xDerived (calculated)
- Current ratio (FY 2025-12-31): 4.20xDerived (calculated)
- Return on assets (FY 2025-12-31): -47.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -614.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -2.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 32.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 1.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 4.6%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 15.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -77.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -6.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 29.2%Derived (calculated)
- Long-term debt (annual): USD 55.65MSEC XBRL filing
- Operating income (annual): USD -33.76MSEC XBRL filing
- Current assets (annual): USD 75.58MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-09 00:00 UTCINSIDER20 insider transactions — 2026-06 10 derivative
2026-06-09INSIDERRocchio Betty Jo transacted 11.7k sh — Director
2026-06-09INSIDERCapper Joseph H transacted 11.9k sh — Director
2026-06-09INSIDERCapper Joseph H transacted 11.7k sh — Director
2026-06-09INSIDERPlovanic William J. transacted 11.7k sh — Director
2026-06-09INSIDERNEELS GUIDO J transacted 11.9k sh — Director
2026-06-09INSIDERNEELS GUIDO J transacted 11.7k sh — Director
2026-06-09INSIDERTHOMAS PAUL transacted 11.9k sh — Director
2026-06-09INSIDERTHOMAS PAUL transacted 11.7k sh — Director
2026-06-09INSIDERNOHRA GUY P transacted 11.9k sh — Director
2026-06-09INSIDERNOHRA GUY P transacted 11.7k sh — Director
2026-06-09INSIDERCapper Joseph H acquired 17.6k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERNOHRA GUY P acquired 17.3k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERNOHRA GUY P acquired 17.6k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERTHOMAS PAUL acquired 17.3k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERTHOMAS PAUL acquired 17.6k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERNEELS GUIDO J acquired 17.3k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERNEELS GUIDO J acquired 17.6k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERPlovanic William J. acquired 17.3k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERRocchio Betty Jo acquired 17.3k sh Stock Option (Right to Buy) — Director
2026-06-09INSIDERCapper Joseph H acquired 17.3k sh Stock Option (Right to Buy) — Director
2026-02-24 00:00 UTCINSIDER23 insider transactions — 2026-02 5 derivative
2026-02-24INSIDERKOBLISH ANTONY transacted 3.9k sh — Director, Chief Executive Officer ~$3k
2026-02-23INSIDERFirestone Gregory A. transacted 1.4k sh — Chief Business Officer ~$1k
2026-02-23INSIDERTalmo Paul transacted 4.1k sh — Chief Technology Officer ~$3k
2026-02-23INSIDERSmeykal Megan transacted 423 sh — Chief Accounting Officer ~$0k
2026-02-23INSIDERCuca Roberto transacted 5.2k sh — COO and CFO ~$4k
2026-02-23INSIDERKOBLISH ANTONY transacted 11.6k sh — Director, Chief Executive Officer ~$9k
2026-02-21INSIDERKOBLISH ANTONY transacted 12.5k sh — Director, Chief Executive Officer ~$9k
2026-02-21INSIDERFirestone Gregory A. transacted 4.2k sh — Chief Business Officer ~$3k
2026-02-21INSIDERTalmo Paul transacted 3.4k sh — Chief Technology Officer ~$2k
Showing the 40 most recent of 60 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage